Dose-Escalating Study of BG9924 in Combination With Methotrexate in Active Rheumatoid Arthritis
Status:
Completed
Trial end date:
2007-05-01
Target enrollment:
Participant gender:
Summary
This Phase 2a study is designed to evaluate the safety and tolerability of multiple
subcutaneous (SC) doses of BG9924, administered in a cohort dose-escalation fashion, in
patients with active rheumatoid arthritis (RA) who have had an inadequate response to therapy
with disease-modifying anti rheumatic drugs (DMARDs) and who may have undergone anti-TNF
therapy. This study will assist with dose selection for further planned Phase 2 studies.